Immune Design to Present at Upcoming Investor Conferences in September
September 01 2017 - 8:00AM
Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company
focused on cancer, today announced that the company will present at
two upcoming investor conferences in September.
2017 Wells Fargo Securities Healthcare
Conference Thursday, September 7, 2017 at 10:00 a.m.
Eastern Time in Boston.
Leerink Partners Roundtable Series: Rare
Disease & Immuno-Oncology Thursday, September 28, 2017
at 10:30 a.m. Eastern Time in New York.
A live webcast of each presentation will be
available online from the investor relations page of the company's
corporate website at http://ir.immunedesign.com/events.cfm.
After the live webcast, an archive of each presentation will
be available on the company website for 30 days.
About Immune Design
Immune Design is a clinical-stage immunotherapy
company employing next-generation in vivo approaches to enable the
body's immune system to fight disease. The company's technologies
are engineered to activate the immune system's natural ability to
generate and/or expand antigen-specific cytotoxic T cells, while
also enhancing other immune effectors, to fight cancer and other
chronic diseases. CMB305 and G100, the primary foci of Immune
Design's ongoing immuno-oncology clinical programs, are products of
its two synergistic discovery platforms, ZVex® and GLAAS®.
Immune Design has offices in Seattle and South San Francisco. For
more information, visit www.immunedesign.com.
Media Contact
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219
Investor Contact
Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Apr 2023 to Apr 2024